Clinical Trial

A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

Name: A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants — clinical trial record (NCT07737717)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-12

Trial Details

NCT Number	NCT07737717
Lead Sponsor	ModernaTX, Inc.
Conditions	Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
Enrollment	84 participants
Start Date	2026-07-31
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-11